Lab automation for biologists is evolving quickly. Trilobio, a startup aiming to simplify scientific workflows, has secured $8 million in seed funding. As News-Medical.net reports, this funding round was led by Initialized Capital, with additional backing from Argon Ventures and Lowercarbon Capital. The new investment will help Trilobio build smarter, more accessible lab automation tools that enhance reproducibility and speed up research.
Why Lab Automation for Biologists Is Urgently Needed
According to Business Wire, nearly 77% of researchers struggle to repeat their own experiments. That’s a major problem in life sciences, where results must be trusted. Errors often happen during manual lab tasks like pipetting or timing procedures. As a result, scientists waste time troubleshooting instead of focusing on new discoveries. Trilobio’s platform aims to fix this through automation, ensuring that every experiment follows the same steps with high precision.
Inside Trilobio’s Next-Generation Lab Platform
Trilobio’s core product is the Trilobot—a flexible robot that performs lab tasks using swappable tools like pipettes and tube handlers. Powered by Trilobio OS, the platform allows researchers to set up and execute lab protocols through a no-code, drag-and-drop interface. As explained in the Trilobio blog, this system makes lab automation for biologists accessible to all labs, not just elite institutions. Furthermore, it helps teams share protocols that are reproducible across different locations.
Future Growth and Industry Impact
Trilobio plans to use the funding to expand its automation library, enhance its software, and integrate more lab devices. These improvements will support advanced research in synthetic biology, diagnostics, and genetic engineering. Moreover, smaller labs that previously lacked automation can now compete with larger facilities. This shift could democratize lab automation and drive innovation across the life sciences.
Explore More
To learn how lab automation and biotech innovation are shaping the future of research, visit InnovateMed.org.
